Decibel Therapeutics, Inc. (DBTX)
| Market Cap | 115.84M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -60.36M |
| Shares Out | 24.96M |
| EPS (ttm) | -2.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 77,620 |
| Open | 4.68 |
| Previous Close | 4.65 |
| Day's Range | 4.40 - 4.72 |
| 52-Week Range | 1.83 - 8.86 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 15.81 (+240.7%) |
| Earnings Date | Aug 8, 2022 |
About DBTX
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for DBTX stock is "Buy." The 12-month stock price forecast is 15.81, which is an increase of 240.73% from the latest price.
News
Decibel Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Update
- Announced positive data from interim analysis of Phase 1b clinical trial of DB-020 in patients receiving cisplatin chemotherapy; data support continued development of DB-020 as a potential therapy to ...
Decibel Therapeutics Delivers Solid Interim Data From Cisplatin-Associated Hearing Loss Study
Decibel Therapeutics Inc (NASDAQ: DBTX) reported positive top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB-020 to protect against hearing loss in cancer patients re...
Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Pati...
- 87% of patients who experienced ototoxicity in their placebo-treated ear were protected from ototoxicity in their DB-020-treated ear –
Decibel Therapeutics to Present at the Jefferies Global Healthcare Conference
BOSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and imp...
Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference
BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and impr...
Decibel Therapeutics Reports First Quarter 2022 Financial Results and Corporate Update
- Multiple milestones anticipated for 2022 including submission of IND and/or CTA for DB-OTO, top-line results from interim analysis of Phase 1b trial of DB-020 for cisplatin-induced hearing loss and pr...
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and impr...
Decibel Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and im...
Decibel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
- Key anticipated catalysts in 2022 include submission of IND and/or CTA for DB-OTO and results from interim analysis from Phase 1b trial of DB-020 for cisplatin-induced hearing loss -
Decibel Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and imp...
Decibel Therapeutics Reports on Continued Progress of Lead Gene Therapy Product Candidate DB-OTO and Presents Promisi...
- Podium presentation at Association for Research in Otolaryngology Annual MidWinter Meeting highlighting DB-OTO dose-ranging studies with expression analysis, functional recovery and tolerability data -
Decibel Therapeutics to Present at the 45th Annual Association for Research in Otolaryngology (ARO) Meeting
BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and imp...
Decibel Therapeutics to Present at the H.C. Wainwright BioConnect Conference
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and imp...
Decibel Therapeutics Announces Appointments of Alison Finger, MBA and Saraswathy Nochur, Ph.D. to its Board of Direct...
BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and imp...
Decibel Therapeutics Announces Extension of Research Term under Strategic Collaboration with Regeneron to Discover an...
BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and imp...
Decibel Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update
- Received Orphan Drug and Rare Pediatric Disease designations for DB-OTO for the treatment of otoferlin-related congenital hearing loss –
Decibel Therapeutics to Present at the Barclays Gene Editing & Gene Therapy Summit
BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and imp...
Decibel Therapeutics to Present at the Jefferies Gene Therapy/Editing Summit
BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and imp...
Decibel Therapeutics Announces Publication of Foundational Study of Noise-related Inner Ear Damage
BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and im...
Decibel Therapeutics' Hearing Loss Gene Therapy Receives FDA Orphan Drug Tag
The FDA has granted both Orphan Drug Designation and Rare Pediatric Disease Designation to Decibel Therapeutics Inc (NASDAQ: DBTX) lead gene therapy product candidate, DB-OTO, for otoferlin-related cong...
Decibel Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO for the Treatment of Oto...
BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and im...
Decibel Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and im...
Decibel Therapeutics Appoints Cynthia Hu as Chief Legal Officer and Corporate Secretary
BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and imp...
Decibel Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
- Bolstered Board of Directors and Scientific Advisory Board with key appointments -
Losers Outnumber Gainers in Biotech IPOs This Year
Is investor enthusiasm for new biotechnology companies waning? Based on the performance of the 35 biotechs that went public in the first quarter, that may be the case.